Trevena, Inc. (NASDAQ:TRVN – Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.24 and traded as low as $1.30. Trevena shares last traded at $1.30, with a volume of 667 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on shares of Trevena in a research report on Wednesday. They set a “sell” rating on the stock.
Get Our Latest Report on Trevena
Trevena Stock Up 1.5 %
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Read More
- Five stocks we like better than Trevena
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Canadian Penny Stocks: Can They Make You Rich?
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- About the Markup Calculator
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.